Stockscreener 앱 받기
33.74
0.92%
-0.33
시간 외 거래:
33.78
0.04
+0.12%
전일 마감가:
$34.07
열려 있는:
$34.03
하루 거래량:
185.24K
Relative Volume:
0.35
시가총액:
$1.10B
수익:
$780.57M
순이익/손실:
$62.87M
주가수익비율:
19.65
EPS:
1.7171
순현금흐름:
$327.58M
1주 성능:
+0.41%
1개월 성능:
+3.87%
6개월 성능:
-26.98%
1년 성능:
+16.97%
1일 변동 폭
$33.57
$34.30
1주일 범위
$33.32
$35.01
52주 변동 폭
$28.73
$50.79
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
명칭
Collegium Pharmaceutical Inc
전화
781-713-3699
주소
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Compare COLL vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COLL
Collegium Pharmaceutical Inc
|
33.77 | 1.11B | 780.57M | 62.87M | 327.58M | 1.7171 |
TAK
Takeda Pharmaceutical Co Adr
|
15.87 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.63 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.24 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
578.43 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-01-10 | 업그레이드 | Needham | Hold → Buy |
| 2024-07-30 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-06-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-05-10 | 다운그레이드 | Needham | Buy → Hold |
| 2024-05-10 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-01-04 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-08-25 | 재확인 | Needham | Buy |
| 2023-05-02 | 재개 | Jefferies | Buy |
| 2022-08-08 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-02-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-01-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-14 | 개시 | BWS Financial | Sell |
| 2020-05-27 | 개시 | Guggenheim | Neutral |
| 2020-02-19 | 재개 | Jefferies | Buy |
| 2019-10-30 | 재확인 | Needham | Buy |
| 2019-05-03 | 재개 | H.C. Wainwright | Buy |
| 2019-04-12 | 재개 | Janney | Buy |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2019-01-16 | 재확인 | Needham | Buy |
| 2018-03-08 | 재확인 | H.C. Wainwright | Buy |
| 2018-02-07 | 재확인 | Needham | Buy |
| 2017-12-05 | 재확인 | Needham | Buy |
| 2017-09-11 | 개시 | H.C. Wainwright | Buy |
| 2017-05-11 | 재확인 | Needham | Buy |
| 2016-09-13 | 개시 | Gabelli & Co | Buy |
| 2015-06-01 | 개시 | Jefferies | Buy |
| 2015-06-01 | 개시 | Needham | Buy |
| 2015-06-01 | 개시 | Piper Jaffray | Overweight |
모두보기
Collegium Pharmaceutical Inc 주식(COLL)의 최신 뉴스
Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q1 - TradingView
(COLL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
How Strong Q1 Earnings and Executive Departures At Collegium Pharmaceutical (COLL) Have Changed Its Investment Story - simplywall.st
Collegium Pharmaceutical stock (US19459E1029): insider trade draws attention as Wall Street sees ups - AD HOC NEWS
Collegium (NASDAQ: COLL) director sells 20 shares, holds 83,952 - Stock Titan
COLL Stock Price, Quote & Chart | COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) - ChartMill
Collegium Pharma Leans on ADHD to Drive Growth - TipRanks
Collegium pharmaceutical director sells $142k in shares By Investing.com - Investing.com South Africa
Collegium pharmaceutical director sells $142k in shares - Investing.com India
Director Nancy Lurker awarded 8,741 RSUs at Collegium (COLL) - Stock Titan
Director Carlos V. Paya granted 8,741 RSUs at COLLEGIUM (NASDAQ: COLL) - Stock Titan
Collegium (COLL) director sells shares, exercises options and receives RSU grant - Stock Titan
Director at Collegium (COLL) awarded 17,482 restricted stock units - Stock Titan
Director at Collegium (NASDAQ: COLL) receives 8,741 RSUs in equity award - Stock Titan
Director at Collegium (NASDAQ: COLL) awarded 8,741 RSUs in equity grant - Stock Titan
COLL (NASDAQ) Form 144 shows 4,127-share sale and 30-share resale notice - Stock Titan
Collegium Pharmaceutical (COLL) director Donovan Glancy files initial Form 3 - Stock Titan
Collegium Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Have Collegium Pharmaceutical Insiders Been Selling Stock? - simplywall.st
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know - Yahoo Finance
Collegium Pharmaceutical stock (US19459E1029): opioid-pain specialist in focus after Q1 2026 earning - AD HOC NEWS
Collegium Shareholders Back Board, Pay and Auditor Choices - TipRanks
Collegium (NASDAQ: COLL) shareholders back board, pay and auditor at 2026 meeting - Stock Titan
Collegium Pharmaceutical (COLL) director sells 4,500 shares in market trade - Stock Titan
Janus Henderson (COLL) reports 1.83M-share, 5.8% holding in PHARMACEUTICAL, INC. - Stock Titan
[SCHEDULE 13G/A] COLLEGIUM PHARMACEUTICAL, INC Amended Passive Investment Disclosure - Stock Titan
[144] COLLEGIUM PHARMACEUTICAL, INC SEC Filing - Stock Titan
Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality - 富途牛牛
Truist Financial Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating - Moomoo
Renaissance files 4.53% holding in PHARMACEUTICAL, INC (COLL) - Stock Titan
Barclays Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Maintains Target Price $56 - Moomoo
Statutory Profit Doesn't Reflect How Good Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are - simplywall.st
Collegium Pharmaceutical's (NASDAQ:COLL) Solid Earnings Are Supported By Other Strong Factors - Yahoo Finance
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics stocks trade down, what you need to know - MSN
Collegium (NASDAQ: COLL) director exercises options, sells 8,700 shares at $37 - Stock Titan
Earnings call transcript: Collegium Pharmaceutical Q1 2026 beats estimates By Investing.com - Investing.com Canada
Collegium Pharmaceutical (NASDAQ: COLL) group filings show shared 4.7% positions - Stock Titan
Collegium Pharmaceutical Completes Azstarys Acquisition, Raises 2026 Net Product Revenue Guidance - Moomoo
Collegium Pharmaceutical Acquires AZSTARYS®, Expanding ADHD Portfolio and Raising 2026 Financial Guidance - Minichart
TradingKey - TradingKey
Collegium Pharmaceutical Completes $650 Million AZSTARYS Acquisition From Corium - citybiz
Collegium Pharmaceutical Completes AZSTARYS ADHD Business Acquisition - TipRanks
Collegium completes acquisition of Azstarys® from Corium Therapeutics - marketscreener.com
AZSTARYS deal lifts Collegium (NASDAQ: COLL) 2026 revenue and EBITDA outlook - Stock Titan
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics - GlobeNewswire
A Look At Collegium Pharmaceutical (COLL) Valuation As Earnings Jump And AZSTARYS Acquisition Is Proposed - Sahm
Responsive Playbooks and the COLL Inflection - Stock Traders Daily
ADHD drug AZSTARYS sells for $650M, with patents lasting to 2037 - Stock Titan
Collegium Pharmaceutical, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:COLL) 2026-05-11 - Seeking Alpha
COLL Q1 Deep Dive: ADHD Portfolio Expansion and Pain Segment Stability Drive Results - Yahoo Finance
1 Healthcare Stock with Competitive Advantages and 2 We Brush Off - The Globe and Mail
Collegium Pharmaceutical Inc (COLL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Collegium Pharmaceutical Inc 주식 (COLL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Freund John Gordon | Director |
May 15 '26 |
Option Exercise |
16.49 |
8,700 |
143,463 |
88,099 |
| Freund John Gordon | Director |
May 15 '26 |
Sale |
34.54 |
4,127 |
142,547 |
83,972 |
5.13%
6.20%
자본화:
|
볼륨(24시간):